Upon activation, PPARγ inhibits NF-κB signaling pathway and dampens gut inflammation by modulating the release of inflammatory mediators and favoring Tregs recruitment during the later stage of experimental IBD [203]. This evidence concerns the gene NFKB1 and inflammatory bowel disease.